Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Optimata Ltd.
"Cancer Research" Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
November 11th, 2008
Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced that a scientific paper based on research carried out by company scientists will be published in the prestigious "Cancer Research" Journal 2008; edition 68: (21), on November, 1st 2008. The paper discusses "Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: a New Theranostic Method Combining Xenografted Biopsies with a Mathematical Model." The study involved the challenging task of personalizing treatment of a cancer patient by using unique technology combining in silico, in vitro and in vivo models. The...
Source: Cancer Weekly (2008-11-11)
|
